Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 4/20 | 0.51 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.35 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11810833 | 0.88 | MEN1 (0.52) | HSD17B1MEN1MAPK1KMT2ANPSR1 | |
| SCHEMBL4812130 | 0.84 | HSD17B1 (0.62) | HSD17B1PBRM1CASP1CASP7HSD17B10 | |
| SCHEMBL4816146 | 0.81 | HSD17B1 (0.54) | HSD17B1HSD17B10MEN1KMT2A | |
| SCHEMBL12306065 | 0.81 | PBRM1 (0.47) | HSD17B1PBRM1CASP1CASP7HSD17B10 | |
| SCHEMBL4814802 | 0.80 | HSD17B1 (0.43) | HSD17B1PBRM1CASP1CASP7HSD17B10 | |
| SCHEMBL13956414 | 0.77 | HSD17B1 (0.41) | HSD17B1PBRM1CASP1CASP7HSD17B10 | |
| SCHEMBL4814033 | 0.75 | HSD17B1 (0.42) | HSD17B1PBRM1CASP1CASP7HSD17B10 | |
| SCHEMBL20681358 | 0.74 | MEN1 (0.54) | HSD17B1PBRM1CASP1CASP7HSD17B10 | |
| SCHEMBL91586 | 0.74 | HSD17B1 (0.55) | HSD17B1CASP1CASP7HSD17B10PTGS2 | |
| SCHEMBL1512782 | 0.74 | PBRM1 (0.53) | HSD17B1PBRM1CASP1CASP7HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109369417-B | Preparation method of 2-aminoindane derivative | 诚达药业股份有限公司 | 2021-07-06 | — | — | CN | disclosed |
| US-9040559-B2 | BETA2-adrenoceptor agonists | NOVARTIS AG (CH) | 2015-05-26 | — | — | US | disclosed |
| US-20140343091-A1 | BETA2-ADRENOCEPTOR AGONISTS | NOVARTIS AG (CH) | 2014-11-20 | — | — | US | disclosed |
| US-8796307-B2 | Beta2-adrenoreceptor agonists | NOVARTIS AG (CH) | 2014-08-05 | — | — | US | disclosed |
| US-20140066478-A1 | Beta2-Adrenoreceptor Agonists | NOVARTIS AG (CH) | 2014-03-06 | — | — | US | disclosed |
| US-8658673-B2 | BETA2-adrenoreceptor agonists | NOVARTIS AG (CH) | 2014-02-25 | — | — | US | disclosed |
| US-20130231367-A1 | BETA2-ADRENORECEPTOR AGONISTS | NOVARTIS AG (CH) | 2013-09-05 | — | — | US | disclosed |
| US-8436017-B2 | Beta-2-adrenoreceptor agonists | NOVARTIS AG (CH) | 2013-05-07 | — | — | US | disclosed |
| EP-2332915-B1 | Beta2-adrenoceptor agonists | NOVARTIS AG (CH) | 2013-02-27 | — | — | EP | disclosed |
| US-20120302531-A1 | beta-2-Adrenoreceptor Agonists | CUENOUD BERNARD (GB) | 2012-11-29 | — | — | US | disclosed |
| US-20050153957-A1 | Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis | NOVARTIS AG (CH) | 2005-07-14 | — | — | US | disclosed |
| US-6878721-B1 | N-(partially hydrogenated fused carbocycle)-2-arylethylamine derivatives, e.g., 8-hydroxy-5-(1-hydroxy-2-(indan-2-ylamino)-ethyl)-1H-quinolin-2-one; treatment of obstructive or inflammatory | NOVARTIS AG (CH) | 2005-04-12 | — | — | US | disclosed |
| US-20050009795-A1 | Mixtures or organic compounds for the treatment of airway diseases | CUENOUD BERNARD (CH) | 2005-01-13 | — | — | US | disclosed |
| US-6800643-B2 | CORTICOSTEROID AND AN INDANYL-QUINOLINONE COMPOUND | NOVARTIS AG (CH) | 2004-10-05 | — | — | US | disclosed |
| CN-1156451-C | Betz 2-adrenoceptor agonists | ��˹��ŵ�� | 2004-07-07 | — | — | CN | disclosed |
| US-20040038951-A1 | Organic compounds | NOVARTIS AG (CH) | 2004-02-26 | — | — | US | disclosed |
| EP-1341542-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002045703-A2 | MIXTURES OR ORGANIC COMPOUNDS FOR THE TREATMENTOF AIRWAY DISEASES | NOVARTIS AG (CH) | 2002-06-13 | — | — | WO | disclosed |
| EP-1183240-A1 | BETA2-ADRENOCEPTOR AGONISTS | Novartis AG (CH) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000075114-A1 | BETA2-ADRENOCEPTOR AGONISTS | NOVARTIS AG (CH) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066478-A1 | Beta2-Adrenoreceptor Agonists | ADRB2, ADRB1, ADRB3 | HSD17B1 1093/4885PBRM1 4125/4885CASP1 3328/4885 |
| US-20140343091-A1 | BETA2-ADRENOCEPTOR AGONISTS | ADRB2, ADRB1, ADRA2A | HSD17B1 1655/4885PBRM1 3575/4885CASP1 3337/4885 |
| US-20040038951-A1 | Organic compounds | CYP11B2, NR3C2, CYP11B1 | HSD17B1 27/4885PBRM1 1006/4885CASP1 337/4885 |
| US-20050153957-A1 | Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis | ADRB3, ADRB2, ADRB1 | HSD17B1 474/4885PBRM1 4692/4885CASP1 3954/4885 |
| US-20130231367-A1 | BETA2-ADRENORECEPTOR AGONISTS | ADRB2, ADRB1, ADRB3 | HSD17B1 938/4885PBRM1 4177/4885CASP1 3068/4885 |
| US-20050009795-A1 | Mixtures or organic compounds for the treatment of airway diseases | NR3C2, CYP11B2, NR3C1 | HSD17B1 27/4885PBRM1 1822/4885CASP1 811/4885 |
| US-20120302531-A1 | beta-2-Adrenoreceptor Agonists | ADRB2, ADRB1, ADRB3 | HSD17B1 1060/4885PBRM1 4042/4885CASP1 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.